At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Trading 11-22 14:14:52 EST
1.40
-0.10
-6.67%
High1.43
Low1.27
Vol659.77K
Open1.35
D1 Closing1.50
Amplitude10.67%
Mkt Cap105.00M
Tradable Cap55.04M
Total Shares75.00M
T/O882.62K
T/O Rate1.68%
Tradable Shares39.31M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Context Therapeutics: A Promising Investment in Innovative Oncology Therapies with Strong Financial Position
BRIEF-Bioatla And Context Therapeutics Announce Exclusive Worldwide License Agreement To Develop And Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Bioatla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize Ba3362, a Nectin-4 X Cd3 T Cell Engaging Antibody
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.